Navigation Links
Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
Date:12/12/2012

BETHESDA, Md., Dec. 12, 2012 /PRNewswire/ --Northwest Biotherapeutics, Inc. (Nasdaq: NWBO; NWBOW), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 450,000 shares of common stock and warrants to purchase 225,000 shares, at a public offering price of $4.00 per share and $0.01 per warrant in connection with its previously announced underwritten public offering of 3,000,000 shares of common stock and warrants to purchase 1,500,000 shares of common stock, bringing total gross proceeds from the offering to $13.8 million.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The Warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance.

Aegis Capital Corp. is acting as the sole book-running manager for this offering. 

A registration statement on Form S-1 relating to the shares and warrants was filed with the Securities and Exchange Commission and is effective.  A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov.  Copies of the final prospectus relating to the offering, may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com., or from the above-mentioned SEC website. 

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax® dendritic cell-based vaccines.  The Company's lead program is a 300-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.   


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
2. HealthWarehouse.com and Northwest Physicians Network Partner to Provide Exclusive Discount Pharmacy Services to Patients
3. Northwest Bio Awarded $5.5 Million German Government Grant
4. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
5. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
6. River Vision Announces Completion of $17 million Series A Financing
7. Winner Medical Announces Closing of Going Private Transaction
8. Alere Inc. Announces Early Results of its Tender Offer and Consent Solicitation for Any and All of its 7.875% Senior Notes due 2016
9. IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
10. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
11. Net Medical Xpress Announces Substantial Teleradiology Growth and Major New Opportunities in Diagnostic/Clinical Crossover Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/19/2017)... R.I. (PRWEB) , ... January 19, 2017 , ... With the cold weather here, many ... , Snow blowers are efficient when clearing large amounts of snow, but they can be ... from the U.S. Consumer Product Safety Commission for the proper use of snow blowers:, ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... engineers, and scientists from around the world, announces the launch of its newly ... and easy portal to research breakthroughs and trending news, vital information on upcoming ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and video ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is announcing ... Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday and ... leading recovery program. , “We know it’s easy to get carried away ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... American Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive ... Health, Dr. Li completed his internship in internal medicine at the Emory University ...
Breaking Medicine News(10 mins):